Clinigen Group (CLIN)

 

CLIN Share PerformanceMore

52 week high827.5 11/01/17
52 week low492.8 16/06/16
52 week change 150.5 (23.15%)
4 week volume6,446,067 21/12/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Change of Joint Broker

RNS Number: 8046T Clinigen Group plc 13 January 2017 13 January 2017 Change of Joint Broker Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it has appointed RBC Capital Markets to act as its Joint Broker with immediate effect. Numis Securities Limited continues to act as Nominated Adviser...

Clinigen and Cumberland enter agreement for Totect

Clinigen Group and Cumberland Pharmaceuticals have announced an exclusive agreement to commercialise the oncology...

Clinigen and Cumberland enter agreement for Totect

Clinigen signs agreement with BioQ Pharma

RNS Number: 8919R Clinigen Group plc 15 December 2016 15 December 2016 CLINIGEN GROUP PLC Clinigen signs Global Access agreement for BioQ Pharma's post-operative pain management product, Ropivacaine Readyfusor Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, announces that its Idis Global A...

Clinigen collaborates with Eisai in South Africa

Clinigen has announced a collaboration with Eisai which provides women in South Africa with access to eribulin for adv...

Clinigen collaborates with Eisai in South Africa

RNS Number: 6197Q Clinigen Group plc 01 December 2016 RNS Reach 1 December 2016 Halaven (eribulin) receives registration in South Africa for treatment of women with advanced breast cancer Collaboration between Eisai and Clinigen provides women in South Africa with access to eribulin for advanced breast cancer Halaven (eribulin) is now registered by th...

Director Deals - Clinigen Group (CLIN)

John Bacon, Non Executive Director, sold 200,000 shares in the company on the 11th November 2016 at a price of 717.00p. T...

Director/PDMR Shareholding

RNS Number: 0896P Clinigen Group plc 14 November 2016 14 November 2016 Director's Share Dealing Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it was notified on 11 November 2016 that the following transaction took place on 11 November 2016. John Bacon, Non-Executive Director, sold 200...

Fundamental DataMore

P/E ratio67.269
EPS11.9
Dividend yield0.5 %

Equity Research (CLIN)

edison investment research
Clinigen Group Plc
01/03/2016
Edison Investment Research is terminating coverage on Clinigen Group (CLIN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be...
edison investment research
Clinigen Group Plc
25/01/2016
Clinigen’s H116 trading statement suggests its business is performing to plan, taking into account some revenue deferrals to H2. The integration of Idis and Link, which we expect to boost its...
edison investment research
Clinigen Group Plc
13/10/2015
Clinigen’s FY15 results demonstrated strong underlying fundamentals, with earnings and net debt better than our forecasts. The integration of Idis and the purchase of Link further its strategy as the...

Latest discussion posts More

  • A bit of hidden good news in anticipation of the up and coming half year trading update on 19th January
    3-Jan-2017
    bushwhacker
  • Re:

    Interesting to have that info Ambiorix1. Thankyou,
    3-Jan-2017
    gravy
  • Re:

    On 30 december Innocoll Holdings announced that it has received a Refusal to File letter from the U.S. Food and Drug Administration for Xaracoll, the company's product ...
    3-Jan-2017
    Ambiorix1

Users' HoldingsMore

Users who hold Clinigen Group also hold..
GLAXOSMITHKLINE21%
BP20%
RDS 'B'18%
TELFORD HOMES17%
LLOYDS GRP.16%

Codes & Symbols

ISINGB00B89J2419
SymbolsCLIN, LSE:CLIN, CLIN.L, CLIN:LN, LON:CLIN, XLON:CLIN